已核实 DOI 相关产品: 63

Mining and Modification of Imine Reductase for Asymmetric Reduction of Cyclic Imines

Journal 2026 · IF 3.9 · 18(1): e01574 · 发表于 2026 年 1 月 14 日
作者: Liya Zhou,Hengrui Zuo,Yunting Liu,Chunliu Li,Ying He,Guanhua Liu,Li Ma,Ruxue Feng,Yanjun Jiang
阅读全文 在 PubMed 查看

摘要

A naturally sourced imine reductase (IRED) was identified from the UniProt database and thoroughly investigated, leading to the identification of an IRED ( Thermostaphylospora chromogena ) typically toward the S -isomer. The mutation E127P/E221A/S236A (denoted as M3) was obtained through combinatorial mutagenesis, which exhibited a wider pH range, significantly improved catalytic activity, and enhanced stability compared to the wild-type Tc IR. M3 demonstrated an enzyme activity of 307.28 ± 3.35 U/g protein and a 7.78-fold increase in catalytic efficiency, clearly outperforming that of Tc IR. A dual enzyme-catalyzed asymmetric synthesis of ( S )-1-methyl-1,2,3,4-tetrahydroisoquinoline (( S )-1-MeTIQ) from 100 mM 1-methyl-3,4-dihydroisoquinoline (1-MeDIQ) was constructed by combining M3 with formate dehydrogenase (FDH, for coenzyme regeneration). This cascade biocatalytic system achieved remarkable results, with a high conversion (> 99%) of 1-MeDIQ and enantioselectivity ( ee value > 98%) of ( S )-1-MeTIQ under optimized reaction conditions. Additionally, this dual-enzyme system was extended to the asymmetric reduction of more cyclic imine substrates, achieving excellent conversion (> 96%) and high ee values > 96%. These findings reveal that M3 is a promising biocatalyst for the efficient, scalable, and stereoselective synthesis of chiral tetrahydroisoquinolines and other chiral N -heterocyclic compounds.

本研究中使用的阿拉丁产品

63 款产品在本文中被引用